Chronic myeloid leukemia disease (CML) found effective therapy by treating patients with tyrosine kinase inhibitors (TKI), which suppress the BCR-ABL1 oncogene activity. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.